This phase 2 randomized clinical trial evaluates the efficacy and safety of Sym004 (a mixture of futuximab and modotuximab) for the treatment of refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy.
http://ift.tt/2nLHspY
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Publication date: Available online 22 March 2017 Source: Medical Journal Armed Forces India Author(s): S.C. Shaw, M.S. Vinod, Amit Devgan ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου